Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + enzastaurin + pemetrexed
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination involves **cisplatin**, a platinum-based chemotherapy drug that interferes with DNA replication; **enzastaurin**, a serine/threonine kinase inhibitor targeting the PI3K/AKT and protein kinase C pathways to suppress tumor cell proliferation and induce apoptosis; and **pemetrexed**, an antifolate antineoplastic agent that inhibits DNA synthesis. The combination aims to enhance antitumor effects by targeting multiple pathways involved in cancer cell growth and survival.
02
Targets
PRKCB (Protein kinase C beta)GART (GAR transformylase)DHFR (Dihydrofolate reductase)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cisplatin + enzastaurin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + enzastaurin + pemetrexed.